Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - tick-borne encephalitis virus (inactivated) antigen - suspension for injection in pre-filled syringe - 0,5 ml - tick-borne meningoencephalitis virus (tbe) - encephalitis, tick borne, inactivated, whole virus

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - tick-borne encephalitis virus (inactivated) antigen - suspension for injection in pre-filled syringe - tick-borne meningoencephalitis virus (tbe) - encephalitis, tick borne, inactivated, whole virus

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - diphtheria toxoid; filamentous haemagglutin ( fha ); haemophilus influenza type b conjugate; hepatitis b surface antigen purified; pertussis toxoid ( pt); poliomyelitis, trivalent, inactivated, whole virus; tetanus toxoid -

Singapúr - enska - HSA (Health Sciences Authority)

biomerieux singapore pte. ltd. - microbiology - the filmarray meningitis/encephalitis (me) panel is a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with filmarray systems. the filmarray me panel is capable of simultaneous detection and identification of multiple bacterial, viral, and yeast nucleic acids directly from cerebrospinal fluid (csf) specimens obtained via lumbar puncture from individuals with signs and/or symptoms of meningitis and/or encephalitis. the filmarray me panel is indicated as an aid in the diagnosis of specific agents of meningitis and/or encephalitis and results are meant to be used in conjunction with other clinical, epidemiological, and laboratory data. results from the filmarray me panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. filmarray me panel is intended to be used in conjunction with standard of care culture for organism recovery, serotyping, and antimicrobial susceptibility testing.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; poliovirus; tetanus toxoid; pertactin; pertussis toxoid; hepatitis b surface antigen recombinant; polyribose ribitol phosphate - haemophilus influenzae type b; diphtheria toxoid -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - poliovirus; pertactin; pertussis filamentous haemagglutinin; pertussis toxoid; diphtheria toxoid; hepatitis b surface antigen recombinant; tetanus toxoid -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

tetanus toxoid; diphtheria toxoid; polyribose ribitol phosphate - haemophilus influenzae type b; poliovirus; pertactin; pertussis toxoid; hepatitis b surface antigen recombinant; pertussis filamentous haemagglutinin -

Singapúr - enska - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - japanese encephalitis virus (live, attenuated, recombinant) - injection, powder, lyophilized, for suspension - 4.0-5.8 log pfu/dose - japanese encephalitis virus (live, attenuated, recombinant) 4.0-5.8 log pfu/dose

Singapúr - enska - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) - injection, suspension - 6 μg/0.5 ml - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) 6 μg/0.5 ml

Kanada - enska - Health Canada

sanofi pasteur limited - rabies vaccine inactivated (human diploid-cell culture) - powder for suspension - 2.5unit - rabies vaccine inactivated (human diploid-cell culture) 2.5unit - vaccines